INDP צמיחת רווח נקי למניה משנה לשנה ב-12 החודשים האחרונים Indaptus

The quarterly EPS percentage change reflects the financial standing of Indaptus Therapeutics (INDP), where 100.00 represents the current level of the metric. The company is utilizing accumulated reserves for early-stage testing in the absence of revenue. Growth is driven by the development of the decOyp platform for tumor combat and M&A potential. The strategy is based on creating bacterial immunotherapies to activate the body's defenses within cancerous tissues.

For Indaptus Therapeutics (INDP), which focuses on early-stage clinical trials and cell line partnerships, profit is a derivative of capital burn efficiency. The history of quarterly earnings per share changes reflects the market reaction to 10-Q reports, allowing for the separation of fundamental business resilience from speculative price volatility driven by investors' emotional perception of drug development timelines.